Massachusetts Society of Clinical Oncologists - Takeda and Seagen to Highlight ADCETRIS® Combination Data Showing Statistically Significant Improvement in Overall Survival for Patients with Advanced Hodgkin's Lymphoma

"The voice for cancer physicians and their patients in Massachusetts."

Home
Resources
For Professionals
Drug Updates
Takeda and Seagen to Highlight ADCETRIS® Combination Data Showing Statistically Significant Improvement in Overall Survival for Patients with Advanced Hodgkin's Lymphoma

Takeda and Seagen to Highlight ADCETRIS® Combination Data Showing Statistically Significant Improvement in Overall Survival for Patients with Advanced Hodgkin's Lymphoma

26 May 2022 5:30 AM | Katy Monaco (Administrator)

Randomized Phase 3 Clinical Trial of ADCETRIS Combination Met Key Secondary OS Endpoint, Demonstrating a 41% Reduction in Risk of Death vs. Standard of Care in Patients With Advanced Hodgkin Lymphoma. Read More.

860 Winter Street, Waltham, MA, 02451
Tel: 781.434.7329 | email: msco@mms.org